Close Menu

GenomeWeb

Bio-Techne said Asuragen's headquarters in Austin, Texas includes a scalable 50,000-square-foot manufacturing facility and CLIA-certified laboratory.

Under the deal, expected to close in April, Agilent will pay $550 million in cash on closing and up to an additional $145 million based on future milestones.

Following completion of the offering of American Depositary Shares, the company will list on the Nasdaq Global Market under the symbol OLK.

At AGBT, UCSC's Karen Miga provided updates on the human pangenome reference project and the telomere-to-telomere consortium's genome assembly work.

The companies will partner on applications including oncology diagnostics, cell-free and circulating tumor DNA assays, and single-cell genomics.

European regulators have begun a rolling review of Russia's Sputnik V SARS-CoV-2 vaccine, Reuters reports.

Science reports that Science Foundation Ireland is seeking annual budget increases.

According to the Financial Times, a UK university group is pushing Elsevier to lower its journal fees.

In Nature this week: satellite tracking and genome sequencing combination used to examine migration patterns of peregrine falcons, and more.

The tumor microenvironment (TME) is comprised of an array of cell types, including immune and inflammatory cells, adipose cells, neuroendocrine cells, and cancer-associated fibroblasts. Additionally, blood and lymphatic vascular networks and extracellular matrix components create a diverse and multifaceted situation. Understanding how all of these elements interact requires the ability to distinguish individual cell types--something that is difficult to do using bulk cell approaches. Single cell gene expression analyses offer a high-resolution understanding of the TME.

Carrier screening to detect the presence of heritable genetic defects has been an important element of reproductive health strategies for over 50 years. Until recently, however, the practice has been restricted to a limited number of single-gene tests offered mainly to higher-risk individuals or populations based on race, ethnicity, or ancestry. But the landscape of carrier screening and its role in reproductive health are changing fast.